Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: Comparison with angiogenesis markers and prognostic factors

Journal of Nuclear Medicine

Volumn 53, Issue 4, 2012, Pages 512-520

  Cochet, Alexandre ^a,b   Pigeonnat, Sophie ^a   Khoury, Blandine ^a   Vrigneaud, Jean Marc ^a   Touzery, Claude ^a   Berriolo Riedinger, Alina ^a   Dygai Cochet, Inna ^a   Toubeau, Michel ^a   Humbert, Olivier ^a   Coudert, Bruno ^a   Fumoleau, Pierre ^a   Arnould, Laurent ^a   Brunotte, François ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b CNRS   (France)

Author keywords

18F FDG; Angiogenesis; Blood flow; Breast cancer

Indexed keywords

CD34 ANTIGEN; ENDOGLIN; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATIONAL STUDY; DRUG TUMOR LEVEL; FIRST PASS EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; SCORING SYSTEM; TUMOR BIOPSY; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ADULT; AGED; BLOOD CIRCULATION; BREAST NEOPLASMS; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84859398531     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096834     Document Type: Article

References (37)

1. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519-530.
2. Mankoff DA, Dunnwald LK, Partridge SC, Specht JM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res. 2009;15: 5294-5296.
3. Semple SI, Gilbert FJ, Redpath TW, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004; 14:2038-2045. (Pubitemid 39481174)
4. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449-4457.
5. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323. (Pubitemid 44392212)
6. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260-268.
7. Laking G, Price P. Radionuclide imaging of perfusion and hypoxia. Eur J Nucl Med Mol Imaging. 2010;37(suppl 1):S20-S29.
8. Mullani NA, Gould KL. First-pass measurements of regional blood flow with external detectors. J Nucl Med. 1983;24:577-581. (Pubitemid 13049707)
9. 15O-labeled water-measured blood flow. J Nucl Med. 2008;49:517-523.
10. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38:1564-1579. (Pubitemid 34876495)
11. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol. 1998;184:119-122.
12. Hu Z, Wang W, Gualtieri EE, et al. LOR-based fully-3D PET image reconstruction using a blob-basis function. In: IEEE Medical Imaging Conference, 2007. Piscataway, NJ: IEEE; 2007. Paper M26-228.
13. Zierler KL. Equations for measuring blood flow by external monitoring of radioisotopes. Circ Res. 1965;16:309-321.
14. Srinivas SM, Dhurairaj T, Basu S, Bural G, Surti S, Alavi A. A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med. 2009;23:341-348.
15. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:13-59.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I, the value of histological grade in breast cancer, experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
17. Zafrani B, Aubriot MH, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000;37:536-545. (Pubitemid 32099165)
18. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
19. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003;30:274-280. (Pubitemid 36686847)
20. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45:1829-1837.
21. Dunnwald LK, Doot RK, Specht JM, et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res. 2011;17:2400-2409.
22. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54:385-395.
23. Duff SE, Li C, Garland JM, et al. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003;17:984-992. (Pubitemid 36676386)
24. Fonsatti E, Altomonte M, Nicotra MR, et al. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 2003;22:6557-6563. (Pubitemid 37372335)
25. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856-861. (Pubitemid 29086739)
26. Dales JP, Garcia S, Bonnier P, et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol. 2003;119:374-380. (Pubitemid 37047860)
27. Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931-1937. (Pubitemid 351551101)
28. Hong H, Yang Y, Zhang Y, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335-1343.
29. Fiedler U, Christian S, Koidi S, et al. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumours. Am J Pathol. 2006;168:1045-1053. (Pubitemid 43327754)
30. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol. 1991;60:85-100.
31. Tchou J, Sonnad SS, Bergey MR, et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol. 2010;12:657-662.
32. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46-52.
33. Specht JM, Kurland BF, Montgomery SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010;16:2803-2810.
34. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res. 1992;52:1592-1597.
35. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509. (Pubitemid 34286345)
36. Beresford MJ, Harris AL, Ah-See M, et al. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 2006;95:1683-1688. (Pubitemid 44950794)
37. Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol. 2009;19:222-228.